Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 35

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9P2H5

UPID:

UBP35_HUMAN

Alternative names:

Deubiquitinating enzyme 35; Ubiquitin thioesterase 35; Ubiquitin-specific-processing protease 35

Alternative UPACC:

Q9P2H5

Background:

Ubiquitin carboxyl-terminal hydrolase 35, also known as Deubiquitinating enzyme 35, plays a crucial role in the ubiquitin-proteasome system. This system is essential for protein degradation and turnover, impacting various cellular processes. The enzyme's alternative names, Ubiquitin thioesterase 35 and Ubiquitin-specific-processing protease 35, reflect its specific activity in cleaving ubiquitin from ubiquitinated proteins, thereby regulating protein stability and function.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 35 could open doors to potential therapeutic strategies. Its involvement in protein degradation pathways suggests its potential impact on diseases characterized by abnormal protein accumulation or degradation, such as neurodegenerative disorders. Targeting this enzyme could lead to novel treatments that modulate protein homeostasis.